Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Status: Enrolling
Updated:  10/4/2017
School of Medicine at the University of Miami
mi
from
Miami, FL
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Status: Enrolling
Updated: 10/4/2017
School of Medicine at the University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Status: Enrolling
Updated:  10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Status: Enrolling
Updated: 10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oral Microbiome and Pancreatic Cancer
Oral Microbiome and Pancreatic Cancer: a Prospective Case-Control Study
Status: Enrolling
Updated:  10/4/2017
New York University School of Medicine
mi
from
New York, NY
Oral Microbiome and Pancreatic Cancer
Oral Microbiome and Pancreatic Cancer: a Prospective Case-Control Study
Status: Enrolling
Updated: 10/4/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Study of PEG-Intron for Plexiform Neurofibromas
A Phase II Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas
Status: Enrolling
Updated:  10/5/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Study of PEG-Intron for Plexiform Neurofibromas
A Phase II Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas
Status: Enrolling
Updated: 10/5/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents
Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents
Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
San Antonio, TX
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Northwestern
mi
from
Chicago, IL
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Northwestern
mi
from
Chicago, IL
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Hurley Medical Center
mi
from
Flint, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Lemmon-Holton Cancer Center
mi
from
Grand Rapids, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Lemmon-Holton Cancer Center
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Sparrow Cancer Center
mi
from
Lansing, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Sparrow Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
St Joseph Mercy Oakland Hospital
mi
from
Pontiac, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
St Joseph Mercy Oakland Hospital
mi
from
Pontiac, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Beaumont Hospital
mi
from
Royal Oak, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
St. Johns Providence
mi
from
Warren, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
St. Johns Providence
mi
from
Warren, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
McLaren Macomb
mi
from
Mount Clemens, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
McLaren Macomb
mi
from
Mount Clemens, MI
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Ronald H. Yanagihara, MD -
mi
from
Gilroy, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Ronald H. Yanagihara, MD -
mi
from
Gilroy, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
San Jose Medical Group
mi
from
San Jose, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
San Jose Medical Group
mi
from
San Jose, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Yale Cancer Center
mi
from
New Haven, CT
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Ochsner Clinic Fndtn
mi
from
New Orleans, LA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Ochsner Clinic Fndtn
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Jefferson City Medical Group
mi
from
Jefferson City, MO
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Jefferson City Medical Group
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Gabrail Cancer Center
mi
from
Canton, OH
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Illinois Cancer Care
mi
from
Peoria, IL
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Hematology-Oncology Associates of Fredericksburg, Inc.
mi
from
Fredericksburg, VA
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Hematology-Oncology Associates of Fredericksburg, Inc.
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated:  10/5/2017
Royal North Shore Hospital
mi
from
Sydney,
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Status: Enrolling
Updated: 10/5/2017
Royal North Shore Hospital
mi
from
Sydney,
Click here to add this to my saved trials
Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer
Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer
Status: Enrolling
Updated:  10/5/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer
Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer
Status: Enrolling
Updated: 10/5/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated:  10/5/2017
Yale University School of Medicine
mi
from
New Haven, CT
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects
Status: Enrolling
Updated: 10/5/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials